LCTX (Lineage Cell Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by LCTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | DEBORAH J ANDREWS | Director | A | — | — |
| 2026-07-02 | Angus C. Russell | Director | A | — | — |
| 2026-07-02 | Neal C Bradsher | Director | A | — | — |
| 2026-07-02 | Anula Jayasuriya | Director | A | — | — |
| 2026-07-02 | Michael H. Mulroy | Director | A | — | — |
| 2026-07-02 | Dipti Amin | Director | A | — | — |
| 2026-03-12 | Brian M Culley | President and CEO | Buy | — | — |
| 2026-03-06 | Jill Ann Howe | Chief Financial Officer | A | — | — |
| 2026-03-06 | Brian M Culley | President and CEO | A | — | — |
| 2026-03-06 | George A. Samuel III | General Counsel and Secretary | A | — | — |
| 2026-02-13 | Brian M Culley | President and CEO | MIXED | — | — |
| 2026-02-13 | George A. Samuel III | General Counsel and Secretary | MIXED | — | — |
| 2025-12-19 | Brian M Culley | President and CEO | MIXED | — | — |
| 2025-12-19 | George A. Samuel III | General Counsel and Secretary | MIXED | — | — |
| 2025-07-03 | Neal C Bradsher | Director | A | — | — |
| 2025-07-02 | Dipti Amin | Director | A | — | — |
| 2025-07-02 | Angus C. Russell | Director | A | — | — |
| 2025-07-02 | DEBORAH J ANDREWS | Director | A | — | — |
| 2025-07-02 | Michael H. Mulroy | Director | A | — | — |
| 2025-07-02 | Anula Jayasuriya | Director | A | — | — |
| 2025-03-12 | George A. Samuel III | General Counsel and Secretary | A | — | — |
| 2025-03-12 | Brian M Culley | President and CEO | A | — | — |
| 2025-03-12 | Jill Ann Howe | Chief Financial Officer | A | — | — |
| 2025-02-12 | George A. Samuel III | General Counsel | MIXED | — | — |
| 2025-02-12 | Brian M Culley | President and CEO | MIXED | — | — |
| 2025-01-28 | NEAL C BRADSHER | Director | Buy | — | — |
| 2024-11-26 | George A. Samuel III | General Counsel | Buy | — | — |
| 2024-11-26 | Jill Ann Howe | Chief Financial Officer | Buy | — | — |
| 2024-11-25 | Michael H. Mulroy | Director | Buy | — | — |
| 2024-11-22 | Brian M Culley | President and CEO | Buy | — | — |
| 2024-08-19 | Jill Ann Howe | Chief Financial Officer | Buy | — | — |
| 2024-07-03 | Michael H. Mulroy | Director | A | — | — |
| 2024-07-03 | Dipti Amin | Director | A | — | — |
| 2024-07-03 | DON M BAILEY | Director | A | — | — |
| 2024-07-03 | DEBORAH J ANDREWS | Director | A | — | — |
| 2024-07-03 | Anula Jayasuriya | Director | A | — | — |
| 2024-07-03 | NEAL C BRADSHER | Director | A | — | — |
| 2024-07-03 | Angus C. Russell | Director | A | — | — |
| 2024-05-28 | Brian M Culley | President and CEO | Buy | — | — |
| 2024-03-08 | Brian M Culley | President and CEO | A | — | — |
| 2024-03-08 | Jill Ann Howe | Chief Financial Officer | A | — | — |
| 2024-03-08 | George A. Samuel III | General Counsel/Secretary | A | — | — |
| 2024-02-12 | George A. Samuel III | General Counsel/Secretary | MIXED | — | — |
| 2024-02-12 | Brian M Culley | President and CEO | MIXED | — | — |
| 2024-02-08 | DON M BAILEY | Director | Buy | — | — |
| 2024-02-08 | BROADWOOD PARTNERS, L.P. | Director | Buy | — | — |
| 2024-01-02 | Anula Jayasuriya | Director | Buy | — | — |
| 2023-07-03 | DON M BAILEY | Director | A | — | — |
| 2023-07-03 | Angus C. Russell | Director | A | — | — |
| 2023-07-03 | Anula Jayasuriya | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 99,121,984 | — |
| — | Director | 83,332,510 | — |
| — | 10%+ Owner | 68,730,970 | — |
| — | Chairman | 5,845,596 | — |
| — | Director | 298,555 | — |
| — | President and CEO | 255,516 | — |
| — | Director | 158,801 | — |
| — | Director | 87,500 | — |
| — | Director | 35,000 | — |
| — | Director | 34,720 | — |
| — | General Counsel and Secretary | 33,565 | — |
| — | Chief Financial Officer | 25,500 | — |
| — | Director | 10,000 | — |
| — | SVP,Clinical & Medical Affairs | 7,710 | — |
| — | Sr Director Finance/Controller | 6,000 | — |
| — | General Counsel/Secretary | 5,000 | — |
| — | CFO & SVP Finance | 5,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LCTX quote page; the site-wide leaderboard is on the insider transactions hub.